Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc., a clinical-stage biopharmaceutical company, has demonstrated a substantial market response with a nearly 500% increase in stock price following the release of the full HARMONi-2 dataset, indicating strong investor sentiment and confidence in its TIL therapies. The company’s DCF analysis suggests a firm value of approximately $884 million, reflecting the potential growth of its autologous tumor infiltrating lymphocyte therapies and the impact of upcoming catalysts within the competitive landscape. Furthermore, Instil Bio is positioned favorably in the market by leveraging innovative approaches that combine checkpoint inhibition with anti-angiogenesis strategies, creating multiple avenues for success in treating various cancer indications.

Bears say

Instil Bio Inc reported a significant increase in its net loss for the fourth quarter of 2024, amounting to $1.82 per share, compared to previous estimates of a loss of $3.65 per share for 2025, projecting a full-year net loss of $11.51 per share. The company faces several key risks that could adversely impact its financial performance, including potential delays in advancing its clinical candidates, the possibility of unfavorable clinical data, particularly for the AXN-2510 therapy in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and risks of medium- to long-term dilution. These factors contribute to an overall negative outlook for the company's financial health and stock performance.

Instil Bio (TIL) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Buy based on their latest research and market trends.

According to 5 analysts, Instil Bio (TIL) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.